UPLOAD Filing
Bio Green Med Solution, Inc.
Date: June 20, 2025 · CIK: 0001130166 · Accession: 0000000000-25-006475
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Cyclacel Pharmaceuticals, Inc. Draft Registration Statement on Form S-4 Submitted on June 16, 2025 CIK No. 0001130166 Dear Datuk Dr. Doris Wong:
June 20, 2025
Datuk Dr. Doris Wong Chief Executive Officer Cyclacel Pharmaceuticals, Inc. Level 10, Tower 11, Avenue 5, The Horizon Bangsar South City, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Debbie A. Klis, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 20, 2025 Datuk Dr. Doris Wong Chief Executive Officer Cyclacel Pharmaceuticals, Inc. Level 10, Tower 11, Avenue 5, The Horizon Bangsar South City, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia Re: Cyclacel Pharmaceuticals, Inc. Draft Registration Statement on Form S-4 Submitted on June 16, 2025 CIK No. 0001130166 Dear Datuk Dr. Doris Wong: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Debbie A. Klis, Esq. </TEXT> </DOCUMENT>